Chat with Filing

Ask questions about this document

Please log in or register to use the chat feature. Please register first.

RNS - Biotest AG: Biotest to present data from TREAT 2b trial at The American College of Rheumatology (ACR) 2015 Annual Meeting

Company: Biotest AG Date: 2015-11-09 Language: English Register to download

Loading document preview...

Document Preview Not Available

The file type (.html) cannot be displayed directly here.

Open Original File

Error loading document preview. Please try the 'Open Original File' link.

You're One Click Away From The Full Filing

Instantly access this document—and 2.8M more—for free. Select your preferred method:

Continue with Google Continue with Microsoft Continue with Facebook Continue with Amazon

 News Details

Corporate | 9 November 2015 10:30

#   

Biotest AG: Biotest to present data from TREAT 2b trial at The American College of Rheumatology (ACR) 2015 Annual Meeting

  

DGAP-News: Biotest AG / Key word(s): Research Update  

  

2015-11-09 / 10:30  

- - -

  

PRESS RELEASE

**Biotest to present data from TREAT 2b trial at The American College of Rheumatology (ACR) 2015 Annual Meeting**

– **Presentation of clinical results from TREAT 2b trial (T cell REgulating Arthritis Trial 2b), evaluating the efficacy, safety and tolerability of its investigational monoclonal antibody, Tregalizumab (BT-061), plus methotrexate combination therapy in patients with moderate to severe rheumatoid arthritis**

– **Preclinical studies are being performed in additional indication and form the basis for a partnering**

*Dreieich, 09 November 2015.* Biotest announced yesterday that an oral presentation of the abstract for tregalizumab (BT-061) will be presented at the 2015 annual meeting of the American College of Rheumatology (ACR), taking place November 6-11, 2015 in San Francisco, California, USA.

Tregalizumab (BT-061) is an investigational, humanised anti-CD4 monoclonal antibody, inducing selective activation of regulatory T-cells. As announced on April 24, 2015, the phase 2b study (TREAT 2b) of tregalizumab (BT-061) in patients with moderate to severe rheumatoid arthritis (RA) did not meet its primary endpoint.

Following a detailed analysis of the data, tregalizumab (BT-061) showed a dose-dependent effect on cells in the immune system which did not translate into marked clinical efficacy in rheumatoid arthritis. The good safety and tolerability profile could be confirmed. Pre-clinical studies are currently being performed in model systems to determine whether tregalizumab (BT-061) could be of benefit in other diseases with high medical need.

The abstract can be accessed on the ACR website at: [http://www.acrabstracts.org](http://public-ir-cockpit.equitystory.com/cgi-bin/fncls.ssp?fn=redirect&url=1ebe6965c030ef2c1306e057e7c2e4ac&application_id=410269&site_id=news_data&application_name=news)

Session Title: **Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy I: Biologics**  

  

Abstract 972: **A Phase 2b Study Evaluating the Efficacy and Safety of Subcutaneously Administered Tregalizumab in Subjects with Active Rheumatoid Arthritis (RA) Despite Treatment with Methotrexate (MTX).**

Oral presentation: November 8, 2015: 2.30 – 4.00 PM (PST)  

  

  

  

Disclaimer

This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and assets position of Biotest AG and its subsidiaries. These statements are based on current plans, estimates, forecasts and expectations of the company and are thus subject to risks and elements of uncertainty that could result in significant deviation of actual developments from expected developments. The forward-looking statements are only valid at the time of publication. Biotest does not intend to update the forward-looking statements and assumes no obligation to do so.

About Biotest

Biotest is a provider of plasma proteins and biological drugs. With a value added chain that extends from pre-clinical and clinical development to worldwide sales, Biotest has specialised primarily in the areas of clinical immunology, haematology and intensive medicine. Biotest develops and markets immunoglobulins, coagulation factors and albumins based on human blood plasma. These are used for diseases of the immune and haematopoietic systems. In addition Biotest develops monoclonal antibodies in the indications of cancer of plasma cells and systemic lupus erythematosus which are produced by recombinant technologies. Biotest has more than 2,200 employees worldwide. The preference shares of Biotest AG are listed in the SDAX on the Frankfurt stock exchange.

Biotest AG, Landsteinerstr. 5, 63303 Dreieich, www.biotest.de  

Dr. Monika Buttkereit  

tel.: +49 (0) 6103 801-4406  

email: investor\_relations@biotest.de

Securities’ ID No., ISIN ordinary shares: 522720, DE0005227201  

Securities’ ID No., ISIN preference shares: 522723, DE0005227235  

Listing: Prime Standard  

Open Market: Berlin-Bremen, Düsseldorf, Frankfurt, Hamburg, Hannover, München, Stuttgart

  

  

  

- - -

2015-11-09 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG.  

The issuer is solely responsible for the content of this announcement.  

  

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.  

Media archive at www.dgap-medientreff.de and www.dgap.de  

- - -

  

|     |     |
| --- | --- |
| Language: | English |
| Company: | Biotest AG |
|     | Landsteinerstraße 5 |
|     | 63303 Dreieich |
|     | Germany |
| Phone: | 0 61 03 – 8 01-0 |
| Fax: | 0 61 03 – 8 01-150 |
| E-mail: | investor\_relations@biotest.de |
| Internet: | http://www.biotest.de |
| ISIN: | DE0005227235, DE0005227201 |
| WKN: | 522723, 522720 |
| Indices: | SDAX |
| Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Stuttgart |
|     |     |     |

|     |     |
| --- | --- |
|     |     |
| End of News | DGAP News Service |

|     |
| --- |
| - - - |
| 410269  2015-11-09 ![show this](http://public-ir-cockpit.equitystory.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=410269&application_name=news&site_id=news_data) |